Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia

{ 'indexed': {'date-parts': [[2022, 1, 10]], 'date-time': '2022-01-10T12:28:10Z', 'timestamp': 1641817690526}, 'reference-count': 38, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 11, 4]], 'date-time': '2020-11-04T00:00:00Z', 'timestamp': 1604448000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': [ 'ijidonline.com', 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['International Journal of Infectious Diseases'], 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.ijid.2020.11.008', 'type': 'journal-article', 'created': {'date-parts': [[2020, 11, 9]], 'date-time': '2020-11-09T18:08:21Z', 'timestamp': 1604945301000}, 'page': '538-543', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 29, 'title': [ 'Randomized controlled open label trial on the use of favipiravir combined with inhaled ' 'interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia'], 'prefix': '10.1016', 'volume': '102', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5107-921X', 'authenticated-orcid': False, 'given': 'Faryal', 'family': 'Khamis', 'sequence': 'first', 'affiliation': []}, {'given': 'Hanan', 'family': 'Al Naabi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adil', 'family': 'Al Lawati', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zaiyana', 'family': 'Ambusaidi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mariam', 'family': 'Al Sharji', 'sequence': 'additional', 'affiliation': []}, {'given': 'Umkulthum', 'family': 'Al Barwani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nenad', 'family': 'Pandak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zakariya', 'family': 'Al Balushi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maher', 'family': 'Al Bahrani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Issa', 'family': 'Al Salmi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3626-4230', 'authenticated-orcid': False, 'given': 'Ibrahim', 'family': 'Al-Zakwani', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2020.11.008_bib0005', 'doi-asserted-by': 'crossref', 'article-title': 'Favipiravir: a new and emerging antiviral option in COVID-19', 'author': 'Agrawal', 'year': '2020', 'journal-title': 'Med J Armed Forces India', 'DOI': '10.1016/j.mjafi.2020.08.004'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0010', 'article-title': 'Experimental Treatment with Favipiravir for COVID-19: an Open-Label ' 'Control Study [published online ahead of print, 2020 Mar 18]', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'issue': '1', 'key': '10.1016/j.ijid.2020.11.008_bib0015', 'doi-asserted-by': 'crossref', 'first-page': '392', 'DOI': '10.1186/s13054-020-03078-z', 'article-title': 'COVID-UTH Study Group. Nafamostat mesylate treatment in combination ' 'with favipiravir for patients critically ill with Covid-19: a case ' 'series', 'volume': '24', 'author': 'Doi', 'year': '2020', 'journal-title': 'Crit Care'}, { 'issue': '1', 'key': '10.1016/j.ijid.2020.11.008_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '58', 'DOI': '10.5582/ddt.2020.01012', 'article-title': 'Discovering drugs to treat coronavirus disease 2019 (COVID-19)', 'volume': '14', 'author': 'Dong', 'year': '2020', 'journal-title': 'Drug Discov Ther'}, { 'issue': '2', 'key': '10.1016/j.ijid.2020.11.008_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '64', 'DOI': '10.1016/j.bsheal.2020.04.004', 'article-title': 'Advanced researches on the inhibition of influenza virus by Favipiravir ' 'and Baloxavir', 'volume': '2', 'author': 'Fang', 'year': '2020', 'journal-title': 'Biosafety Health'}, { 'issue': '3', 'key': '10.1016/j.ijid.2020.11.008_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '307', 'DOI': '10.1017/S0317167100014244', 'article-title': 'Treatment optimization in MS: Canadian MS Working Group updated ' 'recommendations', 'volume': '40', 'author': 'Freedman', 'year': '2013', 'journal-title': 'Can J Neurol Sci'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0035', 'article-title': 'A clinical pilot study on the safety and efficacy of aerosol inhalation ' 'treatment of IFN-κ plus TFF2 in patients with moderate COVID-19', 'volume': '25', 'author': 'Fu', 'year': '2020', 'journal-title': 'E Clin Med'}, { 'issue': '2', 'key': '10.1016/j.ijid.2020.11.008_bib0040', 'doi-asserted-by': 'crossref', 'first-page': '446', 'DOI': '10.1016/j.antiviral.2013.09.015', 'article-title': 'Favipiravir (T-705), a novel viral RNA polymerase inhibitor', 'volume': '100', 'author': 'Furuta', 'year': '2013', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study on hydroxychloroquine in hospitalized patients with ' 'COVID-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '9', 'key': '10.1016/j.ijid.2020.11.008_bib0050', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1002/psp4.12543', 'article-title': 'Timing of Antiviral Treatment Initiation is Critical to Reduce ' 'SARS-CoV-2 Viral', 'volume': '9', 'author': 'Gonçalves', 'year': '2020', 'journal-title': 'CPT Pharmacometrics Syst Pharmacol'}, { 'issue': '10238', 'key': '10.1016/j.ijid.2020.11.008_bib0055', 'doi-asserted-by': 'crossref', 'first-page': '1695', 'DOI': '10.1016/S0140-6736(20)31042-4', 'article-title': 'Triple combination of interferon beta-1b, lopinavir-ritonavir, and ' 'ribavirin in the treatment of patients admitted to hospital with ' 'COVID-19: an open-label, randomised, phase 2 trial', 'volume': '395', 'author': 'Hung', 'year': '2020', 'journal-title': 'Lancet'}, { 'issue': '6', 'key': '10.1016/j.ijid.2020.11.008_bib0060', 'doi-asserted-by': 'crossref', 'first-page': '1102', 'DOI': '10.1016/j.clinthera.2008.06.013', 'article-title': 'Tolerability and safety profile of 12- to 28-week treatment with ' 'interferon beta-1b 250 and 500 microg QOD in patients with ' 'relapsing-remitting multiple sclerosis: a multicenter, randomized, ' 'double-blind, parallel-group pilot study', 'volume': '30', 'author': 'Hurwitz', 'year': '2008', 'journal-title': 'Clin Ther'}, { 'issue': '43', 'key': '10.1016/j.ijid.2020.11.008_bib0065', 'doi-asserted-by': 'crossref', 'first-page': '26955', 'DOI': '10.1073/pnas.2014441117', 'article-title': 'Favipiravir at high doses has potent antiviral activity in ' 'SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity', 'volume': '117', 'author': 'Kaptein', 'year': '2020', 'journal-title': 'Proct Natl Acad Sci USA'}, { 'issue': '3', 'key': '10.1016/j.ijid.2020.11.008_bib0070', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.5001/omj.2020.60', 'article-title': 'Epidemiology of COVID-19 infection in Oman: analysis of the first 1304 ' 'cases', 'volume': '35', 'author': 'Khamis', 'year': '2020', 'journal-title': 'Oman Med J'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0075', 'first-page': '1', 'article-title': 'Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 ' 'Pandemic: a Recent Update', 'author': 'Kumari', 'year': '2020', 'journal-title': 'Curr Pharmacol Rep'}, { 'issue': '7', 'key': '10.1016/j.ijid.2020.11.008_bib0080', 'doi-asserted-by': 'crossref', 'first-page': '1838', 'DOI': '10.1007/s00415-013-6888-0', 'article-title': 'Efficacy and safety of interferon beta-1b sc in older RRMS patients--a ' 'posthoc analysis of the BEYOND study', 'volume': '260', 'author': 'Lampl', 'year': '2013', 'journal-title': 'J Neurol'}, { 'issue': '3', 'key': '10.1016/j.ijid.2020.11.008_bib0085', 'doi-asserted-by': 'crossref', 'first-page': '365', 'DOI': '10.1016/j.jmii.2020.02.001', 'article-title': 'Emerging threats from zoonotic coronaviruses-from SARS and MERS to ' '2019-nCoV', 'volume': '53', 'author': 'Lee', 'year': '2020', 'journal-title': 'J Microbiol Immunol Infect'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0090', 'doi-asserted-by': 'crossref', 'article-title': 'Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV', 'author': 'Lokugamage', 'year': '2020', 'journal-title': 'J Virol', 'DOI': '10.1128/JVI.01410-20'}, { 'issue': '1', 'key': '10.1016/j.ijid.2020.11.008_bib0095', 'doi-asserted-by': 'crossref', 'first-page': '69', 'DOI': '10.5582/bst.2020.01020', 'article-title': 'Drug treatment options for the 2019-new coronavirus (2019-nCoV)', 'volume': '14', 'author': 'Lu', 'year': '2020', 'journal-title': 'Biosci Trends'}, { 'issue': '8', 'key': '10.1016/j.ijid.2020.11.008_bib0100', 'doi-asserted-by': 'crossref', 'first-page': '907', 'DOI': '10.1007/s40262-015-0364-1', 'article-title': 'Ebola Virus Infection: Review of the Pharmacokinetic and ' 'Pharmacodynamic Properties of Drugs Considered for Testing in Human ' 'Efficacy Trials', 'volume': '55', 'author': 'Madelain', 'year': '2016', 'journal-title': 'Clin Pharmacokinet'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0105', 'doi-asserted-by': 'crossref', 'first-page': '70', 'DOI': '10.1016/j.antiviral.2015.08.015', 'article-title': 'Ebola virus dynamics in mice treated with favipiravir', 'volume': '123', 'author': 'Madelain', 'year': '2015', 'journal-title': 'Antiviral Res'}, { 'issue': '6', 'key': '10.1016/j.ijid.2020.11.008_bib0110', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pntd.0008259', 'article-title': 'The safety profile of favipiravir should not be the first argument to ' 'suspend its evaluation in viral hemorrhagic fevers', 'volume': '14', 'author': 'Malvy', 'year': '2020', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0115', 'series-title': 'Phase 3 efficacy and safety study of favipiravir for treatment of ' 'uncomplicated influenza in adults', 'author': 'MDVI, LLC', 'year': '2020'}, { 'issue': '2', 'key': '10.1016/j.ijid.2020.11.008_bib0120', 'doi-asserted-by': 'crossref', 'first-page': '150', 'DOI': '10.1016/S1473-3099(14)71047-3', 'article-title': 'Dose regimen of favipiravir for Ebola virus disease', 'volume': '15', 'author': 'Mentré', 'year': '2015', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0125', 'series-title': 'Number of registered corona virus (COVID-19): Cases in Oman-update', 'author': 'Ministry of Health Oman', 'year': '2020'}, { 'issue': '9390', 'key': '10.1016/j.ijid.2020.11.008_bib0130', 'doi-asserted-by': 'crossref', 'first-page': '1159', 'DOI': '10.1016/S0140-6736(03)14484-4', 'article-title': 'Treatment of SARS with human interferons', 'volume': '362', 'author': 'Moriguchi', 'year': '2003', 'journal-title': 'Lancet'}, { 'issue': '2', 'key': '10.1016/j.ijid.2020.11.008_bib0135', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pntd.0005389', 'article-title': 'Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI ' 'trial reveals concentrations lower than targeted', 'volume': '11', 'author': 'Nguyen', 'year': '2017', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0140', 'doi-asserted-by': 'crossref', 'first-page': '17', 'DOI': '10.1016/j.antiviral.2014.02.014', 'article-title': 'Successful treatment of advanced Ebola virus infection with T-705 ' '(favipiravir) in a small animal model', 'volume': '105', 'author': 'Oestereich', 'year': '2014', 'journal-title': 'Antiviral Res'}, { 'issue': '2', 'key': '10.1016/j.ijid.2020.11.008_bib0145', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/S2055-6640(20)30016-9', 'article-title': 'A review of the safety of favipiravir - a potential treatment in the ' 'COVID-19 pandemic?', 'volume': '6', 'author': 'Pilkington', 'year': '2020', 'journal-title': 'J Virus Erad'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0150', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104791', 'article-title': 'Type 1 interferons as a potential treatment against COVID-19', 'volume': '178', 'author': 'Sallard', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0155', 'series-title': 'Coronavirus Diseases 19 (COVID-19) Protocol for Patients Suspected ' 'Confirmed with COVID-9. Supportive care and antiviral treatment of ' 'suspected or confirmed COVID-19 infection', 'author': 'Saudi Ministry of Health', 'year': '2020'}, { 'issue': '10238', 'key': '10.1016/j.ijid.2020.11.008_bib0160', 'doi-asserted-by': 'crossref', 'first-page': '1670', 'DOI': '10.1016/S0140-6736(20)31101-6', 'article-title': 'Interferon beta-1b for COVID-19', 'volume': '395', 'author': 'Shalhoub', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0165', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.pharmthera.2020.107512', 'article-title': 'Favipiravir, an anti-influenza drug against life-threatening RNA virus ' 'infections', 'volume': '209', 'author': 'Shiraki', 'year': '2020', 'journal-title': 'Pharmacol Ther'}, { 'issue': '3', 'key': '10.1016/j.ijid.2020.11.008_bib0170', 'doi-asserted-by': 'crossref', 'first-page': 'e1001967', 'DOI': '10.1371/journal.pmed.1001967', 'article-title': 'Experimental Treatment with Favipiravir for Ebola Virus Disease (the ' 'JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept ' 'Trial in Guinea', 'volume': '13', 'author': 'Sissoko', 'year': '2016', 'journal-title': 'PLoS Med'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0175', 'doi-asserted-by': 'crossref', 'article-title': 'Dosing will be a key success factor in repurposing antivirals for ' 'COVID‐19', 'author': 'Smith', 'year': '2020', 'journal-title': 'Br J Clin Pharmacol', 'DOI': '10.1111/bcp.14314'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0180', 'article-title': 'Hydroxychloroquine in patients mainly with mild to moderate COVID-19: ' 'an open-label, randomised, controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0185', 'series-title': 'National Guidelines for Clinical Management and Treatment of COVID-19', 'author': 'United Arab Emirates Ministry of Health and Prevention', 'year': '2020'}, { 'key': '10.1016/j.ijid.2020.11.008_bib0190', 'series-title': 'WHO declares COVID-19 as a global pandemic', 'author': 'World Health Organization', 'year': '2020'}], 'container-title': ['International Journal of Infectious Diseases'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220323195?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971220323195?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 4, 21]], 'date-time': '2021-04-21T21:32:08Z', 'timestamp': 1619040728000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 38, 'alternative-id': ['S1201971220323195'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2020.11.008', 'relation': {}, 'ISSN': ['1201-9712'], 'issn-type': [{'value': '1201-9712', 'type': 'print'}], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Randomized controlled open label trial on the use of favipiravir combined with ' 'inhaled interferon beta-1b in hospitalized patients with moderate to severe ' 'COVID-19 pneumonia', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2020.11.008', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 The Authors. Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}